logo
Share SHARE
FONT-SIZE Plus   Neg

Impax Labs. Introduces Oxymorphone Hydrochloride Extended-Release Tablets

Impax Laboratories Inc.(IPXL) said it is commencing shipment of Oxymorphone Hydrochloride Extended-Release Tablets, via. Global Pharmaceuticals, Impax's generics unit.

In June 2010, Impax inked a deal with Endo Pharmaceuticals and Penwest Pharmaceuticals to settle U.S. patent litigation concerning the production and sale of its Oxymorphone Hydrochloride Extended-Release Tablets approved by the U.S. Food and Drug Administration as therapeutically equivalent to the original formulation of OPANA ER. According to the settlement, Endo agreed to grant Impax a license to sell Impax's approved product on January 1, 2013.

Impax also noted that it is actively participating in efforts to support prescriber and patient education of this product through the FDA-approved Risk Evaluation and Mitigation Strategy. Oxymorphone Hydrochloride Extended-Release Tablets are indicated for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Yelp Inc. (YELP) on Monday posted a loss for the fourth quarter compared to a profit last year, as higher revenues were offset by increase in operating costs. Yelp said its Chief Financial Officer Rob Krolik was leaving the company. Yelp reported fourth-quarter loss of $22.2 million or $0.29 per share,... Twenty-First Century Fox Inc., (FOXA, FOX) on Monday reported a second-quarter profit that dropped from last year, hurt largely by lower revenues as strong cable and television advertising revenues were offset by lower filmed entertainment division. Earnings for the quarter trumped Wall Street estimates... Toy maker Hasbro Inc. (HAS) reported a profit for the fourth-quarter 2015 that grew about 3.5% from last year. Quarterly net revenues increased 13% from the prior year. Both earnings per share and revenue for the quarter beat analysts' expectations.
comments powered by Disqus
RELATED NEWS
Trade IPXL now with 
Follow RTT